PRI-724 (Foscenvivint) selectively disrupts CBP/β-catenin interaction driving cancer stem cell differentiation
Copy code to add this image to your page
Targeting nuclear transcription factors remains a central challenge in molecular oncology due to large protein-protein interaction interfaces lacking traditional enzymatic pockets. PRI-724 (Foscenvivint) functions as a second-generation, small-molecule antagonist specifically engineered to disrupt the biochemical interaction between β-catenin and its transcriptional coactivator, Cyclic AMP Response Element-Binding Protein (CBP). Biochemical binding assays confirm high specificity for the CBP/β-catenin interface, yielding an IC50 of approximately 150 nM. Crucially, the compound exhibits no significant inhibitory activity against the structurally homologous coactivator p300 (E1A binding protein p300), despite shared sequence homologies between the two transactivation domains.
The functional consequence of this selective antagonism centers on transcriptional coactivator competition. Under baseline oncogenic signaling conditions, nuclear β-catenin preferentially complexes with CBP. This binding event initiates transcriptional programs that reinforce stemness, suppress differentiation marker expression, and drive resistance to standard chemotherapeutic agents. Upon introduction of PRI-724 (Foscenvivint), CBP is competitively displaced from β-catenin. Free nuclear β-catenin subsequently shifts toward binding p300. This switch in coactivator usage redirects the downstream transcriptional output from self-renewal programs toward gene networks governing lineage commitment and terminal differentiation.
Cellular division dynamics differ fundamentally between malignant stem cells and non-transformed somatic stem cells. Cancer stem cells (CSCs) preferentially undergo symmetric cell division; both daughter cells retain self-renewing, pluripotency-maintaining characteristics. In contrast, normal tissue-resident somatic stem cells rely on asymmetric division to generate one self-renewing cell and one committed progenitor. By forcing a switch from CBP to p300 recruitment, CBP/β-catenin inhibition disrupts symmetric division in CSCs. The treatment forces these malignant cells into a differentiative division pathway, thereby depleting the self-renewing tumor-initiating pool.
Experimental evaluation in patient-derived primary tumor isolates demonstrates that this mechanism clears resistant stem cell subpopulations from their specialized niches. Because normal somatic stem cells preserve their asymmetric division capacity through distinct compensatory mechanisms, the agent achieves selective target clearance without triggering catastrophic normal stem cell exhaustion. In vivo mouse xenograft models and early-phase clinical evaluations substantiate these findings; preliminary Phase I clinical trial data demonstrate manageable toxicity profiles alongside biomarker evidence of Wnt pathway modulation in drug-resistant solid tumors and hematologic malignancies.
Pharmacological Evaluation and Stem Cell Niche Clearance
Copy code to add this image to your page
PRI-724 (Foscenvivint) selectively antagonizes the interaction between β-catenin and the transcriptional coactivator CBP with an IC50 of approximately 150 nM. By inhibiting CBP recruitment without affecting p300, the molecule shifts nuclear β-catenin toward p300 binding. This coactivator switch drives cancer stem cells from self-renewal into terminal differentiation. Because cancer stem cells rely on symmetric cell division, this shift leads to selective depletion of tumor-initiating populations in preclinical and Phase I clinical studies while preserving asymmetric division in normal somatic stem cells.
Selective CBP Coactivator Antagonism Forces Lineage Commitment
Competitive binding assays demonstrate that Foscenvivint selectively displaces nuclear β-catenin from CBP without disrupting p300 assembly. Coactivator binding assays yield a selective IC50 of 150 nM against the CBP complex. Consequently, nuclear β-catenin redirects its binding capacity exclusively toward p300 coactivator complexes. Downstream gene expression shifts rapidly; pluripotency markers decline while differentiation genes show marked upregulation. Differentiation markers increased three-fold within 48 hours of exposure in patient-derived cell models. The agent alters transcriptional trajectories without completely suppressing total β-catenin protein abundance.
Symmetric Division Disruption Clears Resistant Stem Pools
Malignant stem cell populations rely on symmetric division to preserve niche clonogenicity. In murine xenograft models of drug-resistant colorectal carcinoma, treatment with Foscenvivint selectively abolished symmetric division cycles. Normal somatic stem cell niches remained functional throughout the dosing regimen. Histological examination confirmed the exhaustion of tumor-initiating cells within the primary lesion. Survival rates improved significantly; secondary tumor re-seeding dropped below detectable limits in serial transplantation assays. The observed therapeutic window reflects profound differences in division biology between normal and transformed stem cell compartments.